SCHEMBL4186945

SCHEMBL4186945

O=C1COc2ccc(O[C@H]3CCNC3)cc2N1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 9/20 0.48
MMP12 P39900 1/20 0.48
ROCK1 Q13464 2/20 0.47
PARP1 P09874 1/20 0.45
GAA P10253 1/20 0.44
PRKCZ Q05513 1/20 0.44
ALDH1A1 P00352 2/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPT P10636 1/20 0.43
DRD2 P14416 1/20 0.43
DRD4 P21917 1/20 0.43
HTR1D P28221 1/20 0.42
HTR1B P28222 1/20 0.42
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13927893 1.00 HTR1A (0.48) HTR1AMMP12ROCK1PARP1GAA
SCHEMBL5220761 1.00 HTR1A (0.48) HTR1AMMP12ROCK1PARP1GAA
Hydrochloric Acid SCHEMBL4184405 0.99 HTR1A (0.48) HTR1AMMP12ROCK1PARP1GAA
Hydrochloric Acid SCHEMBL4195942 0.99 HTR1A (0.48) HTR1AMMP12ROCK1PARP1GAA
SCHEMBL13927967 0.93 ROCK1 (0.49) HTR1AMMP12ROCK1PARP1GAA
SCHEMBL5214545 0.93 ROCK1 (0.49) HTR1AMMP12ROCK1PARP1GAA
SCHEMBL5248767 0.92 HTR1A (0.52) HTR1AMMP12ROCK1PARP1GAA
Hydrochloric Acid SCHEMBL4188753 0.92 ROCK1 (0.48) HTR1AMMP12ROCK1PARP1GAA
Hydrochloric Acid SCHEMBL4184444 0.91 HTR1A (0.52) HTR1AMMP12ROCK1PARP1GAA
SCHEMBL5217063 0.80 SLC6A4 (0.52) HTR1AMMP12PARP1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042874-A1 ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS WYETH (US) 2009-02-12 US disclosed
US-20090042874-A1 ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS WYETH (US) 2009-02-12 US disclosed
US-20090042874-A1 ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS WYETH (US) 2009-02-12 US disclosed
WO-2008150848-A1 ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS WYETH (US) 2008-12-11 WO disclosed
WO-2008150848-A1 ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS WYETH (US) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042874-A1 ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS HTR5A, CRH, CYP17A1 HTR1A 77/4885MMP12 4356/4885ROCK1 4537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.